Nextgen Bioscience Co. Ltd. has identified new sphingosine 1-phosphate S1P1 and S1P4 receptor antagonists potentially useful for the treatment of autoimmune diseases, ulcerative colitis and Crohn’s disease.
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
Hangzhou Qihan Biotech Co. Ltd. has obtained IND clearance from the FDA for QT-019C, a universal allogeneic CAR T-cell therapy for autoimmune diseases. QT-019C cell injection is an off-the-shelf allogeneic CAR T-cell therapy engineered from healthy donor leukapheresis products to stably express two distinct CARs targeting CD19 and BCMA.
